The IQFISH panel for lung cancer is a set of oligonucleotide-based FISH probes, premixed with IQFISH Buffer, for the detection of rearrangements involving the ALK, ROS, and RET genes, and the detection of MET gene amplification by fluorescence in situ hybridization (FISH). These probes are to be used on lung paraffin-embedded tissue sections. Non–small cell lung cancer may involve genetic aberrations that can be used to direct therapy. For example, a fusion of ALK with EML4 occurs in about 5% of cancers and is linked to strong patient response to treatment with crizotinib. Fusions of ROS1 and RET or amplification of MET are also observed with potential treatment indication. Identification of these abnormalities is often done using FISH. This panel combines new generations of FISH technologies, pairing oligonucleotide-based SureFISH technology with a ready-to-use formulation of formamide-free IQ Hybridization Buffer, resulting in high signal-to-noise ratios with less than 4 hours of turnaround time.